Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
411
-
Total 13F shares, excl. options
-
113M
-
Shares change
-
+1.42M
-
Total reported value, excl. options
-
$18.5B
-
Value change
-
+$219M
-
Put/Call ratio
-
1.41
-
Number of buys
-
205
-
Number of sells
-
-194
-
Price
-
$163.29
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q1 2022
510 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2022.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 411 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 113M shares
of 132M outstanding shares and own 86.22% of the company stock.
Largest 10 shareholders include FMR LLC (16M shares), VANGUARD GROUP INC (10.8M shares), BAILLIE GIFFORD & CO (10.1M shares), BlackRock Inc. (7.61M shares), WELLINGTON MANAGEMENT GROUP LLP (7.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.79M shares), Capital World Investors (6M shares), Dodge & Cox (5.48M shares), JPMORGAN CHASE & CO (2.92M shares), and STATE STREET CORP (2.91M shares).
This table shows the top 411 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.